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Abstract
Background
Medical abortion (mifepristone and misoprostol) has the potential to contribute to reduced
maternal mortality but little is known about the provision or quality of advice for medical
abortion through the private retail sector. We examined the availability of medical abortion
and the practices of pharmacists in India, where abortion has been legal since 1972.
Methods
We interviewed 591 pharmacists in 60 local markets in city, town and rural areas of Madhya
Pradesh. One month later, we returned to 359 pharmacists with undercover patients who
presented themselves unannounced as genuine customers seeking a medical abortion.
Results
Medical abortion was offered to undercover patients by 256 (71.3%) pharmacists and 24 dif-
ferent brands were identified. Two thirds (68.5%) of pharmacists stated that abortion was il-
legal in India. Only 106 (38.5%) pharmacists asked clients the timing of the last menstrual
period and 38 (13.8%) requested to see a doctor’s prescription – a legal requirement in
India. Only 59 (21.5%) pharmacists correctly advised patients on the gestational limit for
medical abortion, 97 (35.3%) provided correct information on how many and when to take
the tablets in a combination pack, and 78 (28.4%) gave accurate advice on where to seek
care in case of complications. Advice on post-abortion family planning was almost
nonexistent.
Conclusions
The retail market for medical abortion is extensive, but the quality of advice given to patients
is poor. Although the contribution of medical abortion to women’s health in India is poorly
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understood, there is an urgent need to improve the practices of pharmacists selling
medical abortion.
Background
The proportion of abortions that are unsafe has increased in recent years [1] and abortion con-
tinues to be a major cause of maternal death, accounting for between 7.9% and 14.9% of mater-
nal deaths worldwide.[2, 3] Of global importance is India where one-quarter of global maternal
deaths are found [2] and 8.8% of maternal deaths are due to abortion.[4]
A pivotal medical advance in the past few decades has been the development of medical
abortion—the use of pills to cause an abortion.[5] Mifepristone combined with misoprostol is
effective, safe and acceptable in various settings,[6–8] including India.[9–11] The private retail
market for medical abortion is thought to be expanding rapidly in India, with sales of miso-
prostol showing a dramatic increase between 2002 and 2007.[12] However, little is known
about the provision or quality of advice for medical abortion through the private retail sector.
Abortion has been legal in India since 1972, when the Medical Termination of Pregnancy
Act came into effect, allowing termination of pregnancy up to 20 weeks gestation under certain
broad conditions. In 2003, an amendment to the regulations permitted medical practitioners
certified to provide surgical abortion to prescribe mifepristone with misoprostol for medical
abortion of pregnancies up to 49 days, on condition the woman has access to a certified abor-
tion facility if complications arise. Despite the liberal abortion law, awareness that abortion is
legal is still limited and concerns about confidentiality, cost and quality of care lead women to
choose uncertified providers closer to home.[13, 14] Abortion services are often not available
at the primary care level in the public sector, and some facilities may lack trained staff, drugs or
equipment necessary for a safe abortion.[15]
We undertook an observational study to understand the scale and quality of the retail mar-
ket for medical abortion in Madhya Pradesh, India. We mapped all health providers in selected
markets, interviewed private pharmacists, returning one month later with undercover patients
to collect information on the availability of medical abortion, the knowledge of the person be-
hind the counter, and the quality of advice given to customers. As efforts are made to reduce
unsafe abortions, it is crucial that better evidence be made available on the role of the retail
market in the provision of medical abortion.
Methods
Study setting
The study took place in the state of Madhya Pradesh, with a population of 73 million living in
50 districts.[16] Two thirds of the population lives in rural areas and 34% of women are illiter-
ate. The maternal mortality ratio was estimated at 277/100,000 live births in 2011–12.[17] Cur-
rent use of modern contraception is 59%, of which the vast majority is female sterilisation.[17]
Only 10% of women use the pill, IUD, injections or condoms. Son preference is strong, as indi-
cated by a male to female sex ratio at birth of 1.10 in 2011–2012.[17]
Sample selection
All districts in Madhya Pradesh were stratified into two groups according to the proportion of
the population living in urban areas in 2011.[16] We randomly selected three highly urbanised
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districts (Bhopal, Indore, and Gwalior) and three rural districts (Satna, Ashoknagar, and
Umaria) (S1 Table). Within each district we randomly selected 10 sampling units in proportion
to sub-district population size.[16] A sampling unit was either an administrative ward in a city,
a block headquarters in a town, or a rural village with a population over 3,000. Smaller villages
were excluded because initial research suggested we would find no pharmacists. Field research-
ers then identified the local market (an agglomeration of pharmacists) in each sampling unit,
took a centre point and limited the area for enumeration to a 1km radius in city areas, and a
2km radius in town and rural areas. The final selection included 20 city, 25 town and 15 rural
local markets.
In each local market, every healthcare provider in the public and private sector was visited
and mapped by their GPS location. Pharmacies were defined as any outlet whose primary busi-
ness was selling medicines, irrespective of whether they were appropriately trained as required
by law. A fixed number of 15 pharmacies (or less where the local market had fewer than 15
pharmacies) were selected for interview by an equal probability systematic sampling. We re-
turned to a random sub-sample of the interviewed pharmacists to gather data using
undercover patients.
Data collection
Trained field researchers interviewed the person behind the counter using a structured ques-
tionnaire on the pharmacist’s background characteristics, the sales, stocks and price of medical
abortion, and the pharmacist’s knowledge of abortion. Information on drugs was collected for
each brand of single misoprostol tablets and combination pack of mifepristone with misopros-
tol. Knowledge tested included the legal status of abortion in India, the gestational limit for
medical abortion, and the dosage and directions of use. A vignette of a medical abortion cus-
tomer was also used to examine the pharmacist’s knowledge of what questions should be asked
to the customer, what advice should be given, and the warning signs of potential complications
from taking the drugs. The field researchers did not prompt for answers to these questions. All
interviews were done in September 2013 by 10 trained field researchers.
We observed the actual quality of advice using a mystery client methodology.[18] One
month after the interview of pharmacists, undercover patients presented themselves unan-
nounced as a customer interested in purchasing a drug without a prescription to induce an
abortion. They were selected to conform closely to the typical customer seen by pharmacists in
the study districts. We used three male and two female clients using two scenarios: a woman
aged 25–30 years who was six weeks pregnant, had heard about medical abortion and was seek-
ing to end the pregnancy; and a man aged 28–30 who was seeking to purchase the drugs on be-
half of his wife who was six weeks pregnant. The undercover patients were trained to rehearse
a standardised script through extensive role play and pre-tests, and to recall accurately the in-
teraction with the pharmacist.
Within an hour of their visit the undercover patients met with their supervisor who used a
structured questionnaire to note the advice given about dosage and directions of use of the
drugs, potential side-effects, warning signs and the need to seek care, and post-abortion family
planning. If no advice was volunteered by the pharmacist, the undercover patients prompted
for information. No medications were purchased since the undercover patients were not carry-
ing a doctor’s prescription; they were instead trained to offer an excuse and end the interaction.
The research ethics committees of the Futures Group in India, Population Council, and
London School of Hygiene and Tropical Medicine approved the study (S1 Appendix). Pharma-
cists provided written informed consent to be interviewed.
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Statistical analysis
We defined medical abortion as misoprostol and mifepristone sold in combination packs or
separately. Availability of medical abortion was measured in three ways: sold by the pharmacist
in the past year; currently in stock at interview; and offered to the undercover patient. We ex-
amined availability at the pharmacist level and within a local market (i.e. available in at least
one pharmacist). Results were stratified by city, town and rural areas and differences were ex-
amined using a χ2 test.
The responses to knowledge questions were coded as either correct, incorrect, or don’t
know. The knowledge of pharmacists measured using the vignette of a medical abortion cus-
tomer was evaluated against a checklist of recommended practice.[19] Finally, we compared
practice and knowledge amongst pharmacists who offered undercover patients any drug(s) to
induce an abortion for a set of indicators that were available in both datasets, using a Wilcoxon
signed rank sum test. Data were analysed using Stata (version 13).
Results
Provision of healthcare and characteristics of pharmacists
Wemapped 1,090 pharmacies in 60 local markets (Fig. 1). The health services available in each
local market are shown in Table 1. Each local market had a median of 13 pharmacies (range
0–67), 11 private doctors (range 0–57), and 1 private hospital (range 0–27), far exceeding the
provision of care in the public sector. The median number of pharmacies was 32 in city (range
7–67), 13 in town (range 3–46) and 2 in rural local markets (range 0–9). Three rural markets
had no pharmacies.
Of the 680 pharmacies sampled, 591 (87%) agreed to be interviewed. The pharmacists were
mostly Hindu, well educated, open every day of the week, and busy (S2 Table). Undercover pa-
tients returned to 359 pharmacists whose characteristics were similar to those interviewed
(S3 Table).
Availability of medical abortion
Table 2 shows that 187 (31.6%) pharmacists reported selling medical abortion in the past year
and 132 (22.3%) had the drugs in stock when interviewed. When presented with an undercover
patient, 256 (71.3%) pharmacists offered medical abortion. The market for medical abortion
was dominated by combination packs. 74 (20.6%) pharmacists offered undercover patients tra-
ditional (ayurvedic) or alternative (homeopathic) drugs (data not shown). There were no sig-
nificant differences by type of location.
Availability of medical abortion in local markets was high (Table 3): 50 (83.3%) local mar-
kets had at least one pharmacist selling medical abortion in the past year and 37 (61.7%) when
measured in terms of current stock. Data from the undercover patients show that medical
abortion was available in 52 (86.7%) local markets. Availability was almost universal in city
and town areas but substantially lower in rural areas.
The interview data suggest that 15 brands of combination pack were available in stock,
while undercover patients were offered 24 different brands (S1 Fig.). The range of brands was
greatest in town areas. In local markets where combination packs were available, the median
number of brands was 2 or 3 depending on data source.
The median price of combination packs was 350 Indian Rupees (£3.82) (Fig. 2). The price
was highest in town areas (median 397 Indian Rupees (£4.33)) and lowest in rural areas (medi-
an 150 Indian Rupees (£1.64)).
Retail Market for Medical Abortion in India
PLOS ONE | DOI:10.1371/journal.pone.0120637 March 30, 2015 4 / 14
Fig 1. Illustration of healthcare provision in a city local market.
doi:10.1371/journal.pone.0120637.g001
Table 1. Healthcare provision at the local market level.
Total City Town (block) Rural (village)
Number of government hospitals 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–0)
Number of government community health centre 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–1)
Number of government primary health centre 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
Number of government health post or sub health centre 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)
Number of private hospitals 1 (0–27) 7 (1–27) 1 (0–5) 0 (0–1)
Number of private gynaecologists 0 (0–6) 0 (0–6) 0 (0–1) 0 (0–0)
Number of private doctors 11 (0–57) 19 (0–57) 9 (2–42) 4 (1–19)
Number of pharmacists 13 (0–67) 32 (7–67) 13 (3–46) 2 (0–9)
The table reports median values and the range in parentheses. There were 60 local markets, of which 3 contained no pharmacists.
doi:10.1371/journal.pone.0120637.t001
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Knowledge of abortion
Two thirds (68.5%) of pharmacists stated that abortion was illegal in India (Table 4). While
347 (58.7%) pharmacists correctly reported how to calculate gestational age, 199 (33.7%) did
not know. One third of pharmacists (31.0%) knew the legal gestational limit for medical
Table 2. Pharmacy availability of medical abortion.
Total City Town (block) Rural (village) P value of
difference
n Availability n Availability n Availability n Availability
Interview data
Sold by pharmacist in past year 591 187
(31.6%)
283 86 (30.4%) 265 85 (32.1%) 43 16 (37.2%) 0.655
Combination pack of medical abortion 591 180
(30.5%)
283 82 (29.0%) 265 84 (31.7%) 43 14 (32.6%) 0.750
Separately sold mifepristone and
misoprostol
591 20 (3.4%) 283 9 (3.2%) 265 9 (3.4%) 43 2 (4.7%) 0.884
Currently in stock 591 132
(22.3%)
283 67 (23.7%) 265 56 (21.1%) 43 9 (20.9%) 0.755
Combination pack of medical abortion 591 128
(21.7%)
283 64 (22.6%) 265 55 (20.8%) 43 9 (20.9%) 0.863
Separately sold mifepristone and
misoprostol
591 10 (1.7%) 283 5 (1.8%) 265 5 (1.9%) 43 0 (0.0%) 0.667
Undercover patient data
Offered to client for sale 359 256
(71.3%)
162 108
(66.7%)
162 123
(75.9%)
35 25 (71.4%) 0.183
Combination pack of medical abortion 359 241
(67.1%)
162 101
(62.4%)
162 117
(72.2%)
35 23 (65.7%) 0.164
Separately sold mifepristone and
misoprostol
359 15 (4.2%) 162 7 (4.3%) 162 6 (3.7%) 35 2 (5.7%) 0.858
P value is from a χ2 test of the difference between the three types of location.
doi:10.1371/journal.pone.0120637.t002
Table 3. Local market availability of medical abortion.
Total City Town (block) Rural (village) P value of difference
n Availability n Availability n Availability n Availability
Interview data
Sold in past year in local market 60 50 (83.3%) 20 19 (95.0%) 25 23 (92.0%) 15 8 (53.3%) 0.001
Combination pack of medical abortion 60 48 (80.0%) 20 18 (90.0%) 25 23 (92.0%) 15 7 (46.7%) 0.001
Separately sold mifepristone and misoprostol 60 17 (28.3%) 20 8 (40.0%) 25 8 (32.0%) 15 1 (6.7%) 0.083
Currently in stock in local market 60 37 (61.7%) 20 17 (85.0%) 25 15 (60.0%) 15 5 (33.3%) 0.008
Combination pack of medical abortion 60 37 (61.7%) 20 17 (85.0%) 25 15 (60.0%) 15 5 (33.3%) 0.008
Separately sold mifepristone and misoprostol 60 9 (15.0%) 20 4 (20.0%) 25 5 (20.0%) 15 0 (0.0%) 0.037
Undercover patient data
Offered to client for sale in local market 60 52 (86.7%) 20 19 (95.0%) 25 25 (100.0%) 15 8 (53.3%) <0.001
Combination pack of medical abortion 60 51 (85.0%) 20 19 (95.0%) 25 24 (96.0%) 15 8 (53.3%) <0.001
Separately sold mifepristone and misoprostol 60 14 (23.3%) 20 7 (35.0%) 25 6 (24.0%) 15 1 (6.7%) 0.145
Medical abortion is available at the local market level if medical abortion is available in at least one pharmacist. Estimates take into account the three rural
local markets that contained no pharmacists to be interviewed. P value is from a χ2 test of the difference between the three types of location.
doi:10.1371/journal.pone.0120637.t003
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abortion in India. When asked the dosage and timing of drugs in combination packs, 44.8%
stated that they did not know. Knowledge was similar amongst the sample of pharmacists who
were approached by an undercover patient (S4 Table). Knowledge of what questions to ask,
what advice should be given, and the warning signs of potential complications were probed
using the data from a vignette of a medical abortion customer (S5 Table).
Knowledge and practice
In Table 5 we examine the practice of pharmacists, comparing this to their knowledge. Only
106 (38.5%) pharmacists asked clients the timing of the last menstrual period and 38 (13.8%)
requested to see a doctor’s prescription—a legal requirement in India. Counselling on dosage
and direction of use was given to 172 (62.5%) clients, but advice on what to expect, warning
signs of possible complications or post-abortion family planning was rarely offered. Only 59
(21.5%) pharmacists correctly advised on the gestational limit for medical abortion, 97 (35.3%)
provided correct information on how many and when to take the tablets in a combination
pack, and 78 (28.4%) gave accurate advice on where to seek medical attention in case
of complications.
The gap between practice and knowledge was generally large (Table 5). For example, two
thirds of pharmacists (67.3%) knew to ask clients the timing of the last menstrual period but
Fig 2. Price of medical abortion combination packs.Central line shows the median value and the box shows the interquartile range (IQR), while the
whiskers represent range of prices. Circles represent statistical outliers—i e, individual chemists with prices outside the range: first quartile–(1.5×IQR) to third
quartile+(1.5×IQR).
doi:10.1371/journal.pone.0120637.g002
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only 38.5% did so in practice. Pharmacists requested to see a doctor’s prescription in only
13.8% of undercover patient interactions, while 35.3% knew this was a question they should
ask. Heavy bleeding was widely recognised (90.9%) as a warning sign but only 49.5% of phar-
macists gave advice on this matter. Many pharmacists (68.0%) knew how many and when to
take the pills in a combination pack but a minority (35.3%) offered the correct advice in prac-
tice. The vast majority of pharmacists (96.7%) knew where to seek care if a complication arose,
while only 28.4% gave such advice.
Discussion
The private retail market for medical abortion in Madhya Pradesh is extensive, but the quality
of advice given to clients is poor. There were on average 13 pharmacies per retail market, over
two-thirds of whom offered medical abortion. Local market availability—a better indicator of
whether local consumers have access to medical abortion—was almost universal in urban set-
tings, albeit lower in rural areas. Knowledge on the legality of abortion was poor, and very few
chemists asked to see a prescription. Only a third of pharmacists asked the gestational age of
Table 4. Knowledge of abortion (interview data).
Number of
pharmacists
Knowledge
Is abortion legal in India?
Correct response (yes) 591 167
(28.3%)
Incorrect response (no) 591 405
(68.5%)
“Don’t know” 591 19 (3.2%)
How do you calculate gestation age?
Correct response (beginning of last menstrual period) 591 347
(58.7%)
Incorrect response (any other response) 591 45 (7.6%)
“Don’t know” 591 199
(33.7%)
Medical abortion is permissible up to how many weeks
pregnant?
Correct response (between 7 and 9 weeks inclusive) 591 183
(31.0%)
Incorrect (more than 9 weeks) 591 164
(27.7%)
Incorrect (less than 7 weeks) 591 163
(27.6%)
“Don’t know” 591 81 (13.7%)
How should combination pack medical abortion drugs be
administered (number of pills and timing)?
Correct response (one tablet of mifepristone on day one, followed
by four tablets of misoprostol on day two or day three)
591 301
(50.9%)
Incorrect response (any other combination) 591 25 (4.2%)
“Don’t know” 591 265
(44.8%)
The limit of gestation for medical abortion was extended from 7 to 9 weeks by the drug comptroller.
Because of the slight ambiguity we allowed any response between 7 and 9 weeks inclusive.
doi:10.1371/journal.pone.0120637.t004
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the woman or correctly advised on how many and when to take the drugs. Advice on post-
abortion family planning was almost nonexistent.
The extensive nature of private healthcare provision in India is well documented.[20] How-
ever, much less is known about the scale of the medical abortion market.[21, 22] One study in
Bihar and Jarkhand examined different types of abortion drugs available but only in pharma-
cists reporting to stock or sell an abortion drug.[23] Our study suggests that medical abortion
is nearly universally available in urban settings, and in half of retail markets in rural areas.
Whether the latter reflects access in rural areas is arguable since we excluded smaller villages
where very few pharmacies are thought to operate.
Why is the market for medical abortion so seemingly vibrant? On the supply side, regulation
of pharmacists and medical abortion is weakly enforced, as suggested by the fact that few phar-
macists requested to see a prescription. On the demand side, a high proportion of women want
an abortion by the time they reach thirty,[14] there is a strong preference for aborting at home,
[8, 24] and the cost of medical abortion is far lower than surgical procedures.[13] The relation-
ship between contraception and abortion is difficult to unpick.[25, 26] But theory suggests that
as desired family size declines, unwanted fertility will rise if the means to prevent pregnancies
are not available or taken up.[27] In this sense, the market for medical abortion is responding
to the considerable numbers of unintended pregnancies.[28] While the ideal number of chil-
dren in Madhya Pradesh has fallen, there has been little change in the use of spacing methods
Table 5. Practice and knowledge (undercover patient and interview data).
Practice
(undercover
patient data)
Knowledge
(interview data)
P value of difference
n Mean n Mean
Asked timing of last menstrual period 275 106 (38.5%) 275 185 (67.3%) <0.001
Asked to see prescription 275 38 (13.8%) 275 97 (35.3%) <0.001
Offered any advice on dosage and directions of use 275 172 (62.5%) 275 202 (73.5%) 0.006
Offered any advice on what to expect after taking drug 275 42 (15.3%) 275 35 (12.7%) 0.385
Offered any advice on warning signs of complications 275 13 (4.7%) 275 72 (26.2%) <0.001
Offered any advice on post abortion family planning 275 4 (1.5%) 275 19 (6.9%) 0.002
Offered any advice on where to seek medical attention 275 4 (1.5%) 275 69 (25.1%) <0.001
Correctly advised heavy bleeding is a warning sign to seek care* 275 136 (49.5%) 275 250 (90.9%) <0.001
Correctly advised severe lower abdominal pain is a warning sign to seek care* 275 35 (12.7%) 275 62 (22.5%) 0.003
Correctly advised severe diarrhoea or vomiting is a warning sign to seek care* 275 6 (2.2%) 275 79 (28.7%) <0.001
Correctly advised high fever is a warning sign to seek care* 275 14 (5.1%) 275 77 (28.0%) <0.001
Correctly advised shivering is a warning sign to seek care* 275 11 (4.0%) 275 40 (14.5%) <0.001
Correctly advised on weeks pregnant MA can be used* 275 59 (21.5%) 275 96 (34.9%) 0.0005
Correctly advised on how many and when to take MA pills* 275 97 (35.3%) 275 187 (68.0%) <0.001
Correctly advised on where to seek care from if needed* 275 78 (28.4%) 275 266 (96.7%) <0.001
Sample limited to pharmacists who were approached by an undercover patient and offered to sell any drug to induce an abortion. P value is from a
Wilcoxon signed rank sum test of the difference between knowledge and practice.
* denotes that the undercover patient prompted for advice related to these indicators if no advice was volunteered by the pharmacist. Correct responses
for the following indicators were deﬁned as: 1) Correctly advised on weeks pregnant medical abortion can be used—responses between 7 and 9 weeks
inclusive were deemed correct; 2) Correctly advised on how many and when to take medical abortion pills—one tablet of mifepristone on day one,
followed by four tablets of misoprostol on day two or day three; and 3) Correctly advised on where to seek care from if needed—any response that
includes private doctor, private hospital, primary health centre, district hospital, tertiary hospital or medical college.
doi:10.1371/journal.pone.0120637.t005
Retail Market for Medical Abortion in India
PLOS ONE | DOI:10.1371/journal.pone.0120637 March 30, 2015 9 / 14
of contraception and the level of use remains extremely low at 9.6%.[17] Reliance on abortion
will only decrease when women are able to control their fertility through other means, particu-
larly temporary methods of contraception. Over the last twenty years, the Indian Government
has tried to move towards a system that addresses individual’s needs but progress has been lim-
ited and uneven, partly because some service providers are reluctant to adopt the principle of
informed choice.[29]
The implications of the expansion of the retail market for medical abortion for women’s
health are not entirely known. It is encouraging that the majority of the products on the market
were combination packs which may help women to take the correct dosage. However, the poor
quality of advice given by pharmacists is worrying, albeit consistent with a number of studies
in India and elsewhere.[22, 30–36] Since few pharmacists established the woman’s gestational
age or gave the correct advice on how many and when to take the drugs, it is possible that a
sizeable number of women who source the combination pack drugs from pharmacists directly
take them incorrectly or too late in pregnancy. Health providers we spoke to in hospitals anec-
dotally report a fall in severe abortion complications coupled with a rise in the number of
women admitted for prolonged bleeding, some of whom develop severe anaemia. There are
very few data on the incidence of abortion morbidity in India.[37] The WHOmulti country
survey on maternal near miss found very few cases due to abortion in hospitals in India but
case definitions were very stringent and cases may have been missed because abortion was not
the focus of the study.[38] The contribution of medical abortion to women’s health in India
thus warrants further investigation.
Our study had several limitations. First, there was no sampling frame with which to select
pharmacies and we sampled proportional to population size within urban and rural districts.
The characteristics of pharmacists and medical abortion availability did not vary by stratum,
nor was there any indication that knowledge or practice varies, and we are confident that the
findings represent the situation on the ground. Second, we only interviewed one person behind
the counter and when comparing practice with knowledge there is no guarantee that we cap-
tured data on the same person. Reassuringly, 99% of respondents in interview were responsible
for the daily running of the shop. Third, we are unable to rely on the interview data to measure
availability of medical abortion and we place much greater weight on the data obtained through
the use of undercover patients. Finally, our study was limited to the retail sector and it would
be informative to know more about medical abortion provision in the public sector.
The widespread informal use of medical abortion represents challenges for the definition
and measurement of unsafe abortion. TheWHO defines unsafe abortion as a procedure for ter-
minating a pregnancy performed by persons lacking the necessary skills or in an environment
not in conformity with minimal medical standards, or both.[39] While pharmacists offer
women an evidence-based procedure, the advice they offer does not conform to minimal medi-
cal standards so the abortion is, strictly speaking, unsafe. Yet most observers will agree that in-
sofar medical abortion has displaced clandestine or riskier methods such as traditional means
of home abortion, fewer women will suffer severe complications or death. The WHO has re-
cently advocated for a more multi-dimensional assessment of the safety of induced abortion,
including the measurement of morbidity.[39] There is a dearth of data on the incidence of
abortion complications and definitions vary substantially.[37] Much can be learned from the
field of obstetrics, where standard definitions are available for complications such as severe
haemorrhage, septicaemia, and anaemia, including near miss.[37, 38] Applying this knowledge
to gain a better understanding of the health consequences of the extensive medical abortion
market should be a priority.
Pharmacists appear to be liberal in selling medical abortion without prescription yet provide
poor counselling to customers, in a context where there is little privacy and interactions
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between the pharmacist and the patient are short. The growth in the unregulated retail market
for medical abortion poses a challenge for government and other agencies concerned with
women’s reproductive health. There are some examples of successful efforts to improve prac-
tice of private pharmacists, through training and other means.[40–42] But the substantial
knowledge-practice gap observed here suggests that increasing knowledge through training
alone may not be sufficient to change practice. Ultimately, efforts to improve practice will re-
quire greater understanding of the incentives faced by pharmacists and how these influence
their practice. In the present situation, clear information leaflets in local languages and stricter
enforcement of existing government regulations without harming access may be the most feasi-
ble path to improvement.
Conclusions
The retail market for medical abortion is extensive, but the quality of advice given to patients is
poor. Although the contribution of medical abortion to women’s health in India is poorly un-
derstood, there is an urgent need to improve the practices of pharmacists selling
medical abortion.
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